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Summary
Objective: Protective effects of SKI 306X, a natural herbal product extracted from three herbs Clematis mandshurica, Trichosanthes kirilowii,
and Prunella vulgaris, on articular cartilage was examined and compared with other osteoarthritis (OA) drugs using in vitro and in vivo
models.
Methods: In vitro culture of rabbit articular cartilage explants was used as a model to measure the effects of drugs on the matrix degradation.
The recombinant human interleukin-1 (rhIL-1, 5 ng/ml) was added to induce proteoglycan (PG) degradation and the degree of PG
degradation was assessed by measuring the amount of glycosaminoglycan (GAG) released into the culture medium. In in vivo experiment,
collagenase was intraarticularly injected twice into the right knee joint of rabbits to induce OA-like change, and test agents were orally
administered once a day for 28 days. The degrees of OA-like changes were evaluated through a histological examination.
Results: In vitro study revealed SKI 306X inhibited the degradation of PG in a concentration-dependent manner. Trichosanthes kirilowii,
which is one of the major components of SKI 306X, also significantly inhibited the GAG release in cartilage explant culture at 0.3 and
0.1 mg/ml. Dexamethasone and NSAIDs, such as diclofenac and rofecoxib, had no significant effects on the suppression of PG degradation.
In in vivo studies, OA-like degeneration of the articular cartilage and synovial tissue was induced by injecting collagenase into the right knee
joint of mature rabbits. At a dose of 200 mg/kg, SKI 306X reduced the OA-like histological changes, whereas diclofenac had no effect at
10 mg/kg.
Conclusion: These results indicate that SKI 306X inhibited PG degradation in cartilage explant culture, and its prophylactic administration
significantly protected the knee joint of rabbit from OA-like change in collagenase-induced experimental OA model. This strongly suggests
that SKI 306X can be a good OA agent with some cartilage protection activity. © 2002 OsteoArthritis Research Society International.
Published by Elsevier Science Ltd. All rights reserved.
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Osteoarthritis (OA) is known to be induced through several
complex mechanisms such as progressive erosion of
articular cartilage, proteoglycan (PG) degradation, and dis-
ruption of the collagen network, leading to a progressive
destruction of joints and functional loss1. The aggregating
cartilage PG, aggrecan, along with type II collagen, is
responsible for the mechanical properties of articular carti-
lage. Aggrecan molecules are composed of two N-terminal
globular domains, G1 and G2, which are separated by an
interglobular domain (IGD), followed by a long central
glycosaminoglycan (GAG) attachment region and a
C-terminal globular domain, G3. Aggrecan monomers inter-
act through the G1 domain with hyaluronic acid and link471proteins to form large molecular weight aggregates, which
are trapped within the cartilage matrix. Aggrecan provides
normal cartilage with compressibility and resilience, and is
one of the first matrix components to undergo measurable
loss in arthritis. The depletion of these macromolecules
results in a decline in the resilience of tissues and the
mechanical stresses transmitted across the joint may con-
tribute to the progression of pathological changes in carti-
lage and subchondral bone. The matrix degradation of
articular cartilage appears to be induced by both extrinsic
and intrinsic factors. Mechanical disturbances and enzy-
matic cleavage by matrix metalloproteinases (MMPs) or
aggrecanases together with cytokines such as interleukin 1
(IL-1) and tumor necrosis factor  (TNF ) are considered
to play critical roles in the degradation of extracellular
matrix components2–5.
Pharmacological management of OA has, up until quite
recently, targeted symptoms of the disease rather than
the underlying cause; analgesics and non-steroidal anti-
inflammatory drugs (NSAIDs) represent the mainstay of
treatment1. These drugs generally decrease pain and stiff-
ness and improve function, but beneficial effects to the
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MATERIALS
Dulbecco’s modified Eagle’s medium (DMEM), heat-
inactivated fetal bovine serum (FBS), and penicillin-
streptomycin were purchased from Gibco BRL (Maryland,
U.S.A.). Recombinant human interleukin-1 (rhIL-1) was
purchased from R&D systems (Minneapolis, U.S.A.), and
the Blyscan proteoglycan & glycosaminoglycan assay kit
from Biocolor (Belfast, N. Ireland). Collagenase (Clostrid-
ium histolyticum, type II; enzyme activity 456 U/mg) was
obtained from Sigma (St Louis, U.S.A.). Dexamethasone
and Diclofenac sodium were purchased from Sigma and
Health Eagle (China), respectively. Rofecoxib was synthe-
sized at the Life Science Research Center of SK Chemicals
(Suwon-si, Korea).PREPARATION AND COMPOSITION OF SKI 306X
SKI 306X was prepared by extracting the mixture of
three medical herbs (dried root of Clematis mandshurica,
dried root of Trichosanthes kirilowii, and dried flower and
stem of Prunella vulgaris at 1:2:1 (w/w), respectively) with
30% (v/v) ethanol in water for 4 h at 80°C. After the
extracted solution was filtered and evaporated in vacuo,
the residue was partitioned between n-butanol and water.
The n-butanol layer was evaporated in vacuo and lyophi-
lized for a complete removal of the residual solvent to yield
dark-brown powder. SKI 306X was standardized to con-
form to the regulations imposed by Korea Food and Drug
Administration (KFDA).ANIMALS
Male New Zealand white rabbits were obtained from
Damool Science (Taejeon, Korea) and housed individually(MJ-161C, Myung Jin Instrument Co., Korea). All animals
had free access to tap water and pellet food (Agribrands,
Purina, Korea). The animal experiments were carried out
according to the internationally accredited guidelines.In vitro study
CARTILAGE EXPLANT CULTURES
Articular cartilages from hock joints of 5-week-old rabbits
were removed immediately after each animal was sacri-
ficed. The articular cartilage explants were obtained by
following the method described by Sandy et al.14–15.
Briefly, after the articular surfaces were exposed surgically
under sterile conditions, approximately 200–220 mg articu-
lar surfaces per joint were dissected and submerged into
complete medium (DMEM, supplemented with heat-
inactivated 5% FBS; penicillin 100 U/ml; streptomycin
100 g/ml). They were then rinsed several times with the
complete medium and incubated for 1 to 2 days at 37°C in
a humidified 5% CO2/95% air incubator for stabilization.
The complete medium was replaced with a basal medium
(DMEM, supplemented with heat-inactivated 1% FBS,
10 mM HEPES, and penicillin 100 U/ml streptomycin
100 µg/ml). Approximately 50 to 60 mg cartilage pieces
(2×3×0.35 mm/piece) were placed in 24-well plates and
treated with given concentrations of test agents. After
pretreatment for 1 h, 5 ng/ml of rhIL-1 was added to the
culture medium and further incubated at 37°C in a humidi-
fied 5% CO2/95% air incubator. The culture medium was
collected 60 h later and stored at −20°C until assay.GLYCOSAMINOGLYCANS MEASUREMENTS
The amount of sulphated GAGs in the medium at the end
of reaction reflecting the amount of PG degradation was
determined by through 1,9-dimethy-methylene blue method
using commercially available kit (The Blyscan proteoglycan
& glycosaminoglycan assay) according to the instructions
of the manufacturer16.In vivo study
COLLAGENASE INJECTION FOR OSTEOARTHRITIS INDUCTION
For in vivo experiment, collagenase was dissolved in
saline at a concentration of 4 mg/ml just before use and the
solution was filtrated with a 0.22 m membrane. Rabbits
weighing 2.5–3.0 kg were grouped (N=5) and anesthetized
with an intramuscular injection of tiletamine-zolazepam
(Zoletil 50®, Virbac, France). After shaving and sterilizing,
the right knee joint was injected intraarticularly with 0.25 ml
of saline or collagenase solution. The injection was per-
formed twice on days 1 and 4 according to the method of
Kikuchi et al.17.PROTOCOL FOR TREATMENT
SKI 306X (200 mg/kg) and diclofenac sodium (10 mg/kg)
were suspended in 0.5% carboxymethylcellulose (CMC)
solution and administered orally in a volume of 10 ml/kg
using feeding catheter (DJ2-284, Dae Jong Ins. Korea)
once a day for 28 days from day 0. Rabbits in control group
were given only 0.5% CMC. In this study, we chose the
10 mg/kg dose of diclofenac sodium based on the clinicalunderlying cartilage and bone changes have not been
demonstrated. Whether NSAIDs are of ‘real’ benefit to the
patient is controversial6–7. Recently, attempts have been
made by several researchers to develop drugs that
reverse, retard or stabilize the underlying pathologic
changes in OA, thus providing long-term symptomatic
relief8–10.
SKI 306X is a purified extract from the mixture of three
oriental herbs, Clematis mandshurica, Trichosanthes kiri-
lowii, and Prunella vulgaris, which have been widely used
for the treatment of inflammatory diseases such as lym-
phadenitis and arthritis in Far East Asia11–12. SKI 306X is
known to have multifunctions such as antiinflammation,
immunomodulation, and the activation of blood microcircu-
lation. In a clinical study on patients with OA, SKI 306X was
revealed to have a good analgesic efficacy and safety
profile and was also suggested to have some cartilage
protective activities13.
In the present study, we investigated the protective
effects of SKI 306X on articular cartilage and compared
them with those of other OA drugs using in vitro and in vivo
models. For in vitro study, rabbit articular cartilage explants
were cultured and recombinant human interleukin 1 (rhIL-
1) was used to induce PG degradation. The amount of
GAG released into the medium was measured as an index
of PG degradation. In vivo experimental OA was induced
via intraarticular collagenase injection in the knee joint of
rabbits, and cartilage destruction and synovial change were
histologically evaluated.
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study, above 20 mg/kg diclofenac showed ulcerogenic
effect in rabbits (data not shown).HISTOPATHOLOGICAL EXAMINATIONS
Rabbits were sacrificed at 28 days after collagenase
injection. The right knee joints were then dissected and
fixed in 10% phosphate-buffered formalin for 2 days and
decalcified with Calci-Clear Rapid solution (National Diag-
nostics, Atlanta, U.S.A.) for 1 week. After decalcification,
dorsal sections were collected from the same anatomical
site on the femoral condyle and tibial plateau as described
by Kikuchi et al, processed routinely, and embedded in
paraffin17. Five micrometer-thin sections were stained with
hematoxylin and eosin (H&E) for light microscopic exami-
nation. The severity of cartilage lesion was graded through
double-blind observations, using the modified histologic
scoring system of Kikuchi et al.17. This system evaluates
the severity of lesion based on the loss of superficial layer,
erosion of cartilage, fibrillation and/or fissures, disorganiz-
ation of chondrocytes, loss of chondrocytes, and cluster
formation. To detect PG loss in cartilage, duplicate sections
were stained with safranin-O method. Articular capsule was
also fixed in formalin and stained with H&E for histolopatho-
logic examination. The severity of synovial lesion was
graded through the histologic scoring system, based on the
hyperplasia of synovial lining cell, hypertrophy of synovial
lining layer, infiltration of inflammatory cells, proliferation of
granulation tissue, and vascularization18. Other parenchy-
mal organs such as stomach, intestine, liver, spleen, and
kidney were also histologically examined to investigate
possible deleterious effects of the test agents.STATISTICS
Data were initially evaluated for normal distribution.
Statistical significances among groups were tested using
Sigma Stat (Jandel Co., San Rafael, CA, U.S.A.) by one
way analysis of variance (ANOVA) and Dunnett’s test or the
Kruskal–Wallis ANOVA and Dunn’s test, depending on
normality of data. test The significances were further con-
firmed by the Student’s t-test or the Mann–Whitney test.
Differences were considered signoficnat when P was less
than 0.05.ResultsIN VITRO STUDYEffects on proteoglycan degradation in cartilage
explant culture
Rabbit cartilage explants were cultured for 60 h with
rhIL-1 (5 ng/ml) in the absence or presence of test agents
to examine the protective effects on PG degradation.Results were expressed as g GAG released into the
medium per mg wet weight of the cartilage (Table I). When
the rabbit cartilage explants were treated with rhIL-1 for
60 h, the amount of released GAG into the culture medium
increased significantly compare to the vehicle group
(4.54±0.59 g/mg vs 1.83±0.28 g/mg).
SKI 306X interfered with the rhIL-1-mediated degra-
dation of PG in a concentration-dependent manner
(P<0.05). SKI 306X at 0.3 mg/ml almost inhibited the PG
degradation. Trichosanthes kirilowii, one of the components
of SKI 306X, also effectively inhibited PG degradation at
0.3 and 0.1 mg/ml. However, the other two components of
SKI 306X, Clematis mandshurica and Prunella vulgaris, did
not show any significant inhibitory effects on PG degra-
dation. There might be synergic effects among the three
components of SKI 306X since the portion of Trichosanthes
kirilowii is about 20% (w/w) in SKI 306X and the chondro-
protective effect of SKI 306X is not totally explained by the
potency of Trichosanthes kirilowii. Diclofenac, a non-
selective cyclooxygenase inhibitor, showed a tendency to
reduce GAG release in a concentration-dependent manner,
which was not statistically significant at all of the concen-
trations. Rofecoxib, a selective COX-2 inhibitor, did not
inhibit PG degradation up to 30 M. Dexamethasone,
reported to inhibit the degradation of collagen network at
10 nM, did not inhibit PG degradation at both concen-
trations of 10 nM and 10 M19.IN VIVO STUDYTable I
The pharmacological effect of SKI 306X, component herbs, and
antiinflammatory agents on GAG release induced by 5 ng/ml
rhIL-1 in rabbit articular cartilage explant culture
Agents Concentration (N) GAG (g/mg)
Vehicle 12 1.83±0.28
rhIL-1 12 4.54±0.59†
SKI 306X 0.3 mg/ml 8 2.02±0.37*
0.1 mg/ml 8 3.28±0.68
0.03 mg/ml 8 4.55±0.70
Trichosanthes kirilowii 0.3 mg/ml 8 2.19±0.17*
0.1 mg/ml 7 2.44±0.20*
0.03 mg/ml 8 3.93±0.49
Clematis mandshurica 0.3 mg/ml 7 4.53±0.39
0.1 mg/ml 7 4.98±0.57
0.03 mg/ml 7 4.89±0.44
Prunella vulgaris 0.1 mg/ml 7 5.09±0.46
0.03 mg/ml 7 4.92±0.21
Diclofenac 30 M 8 2.94±0.19
10 M 8 3.93±0.43
3 M 8 4.41±0.34
Rofecoxib 30 M 8 4.52±0.49
10 M 7 4.88±0.32
3 M 7 4.80±0.38
Dexamethasone 10 M 8 4.23±0.43
10 nM 7 4.50±0.22
Cartilage explants were incubated for 60 h in DMEM with 1%
heat-inactivated FBS and 10 mM HEPES.
Each data represents the mean±S.D.
†P<0.001 vs vehicle, *P<0.05 vs rhIL-1.Gross observations
Kikuchi et al. reported that intraarticularly injected colla-
genase digests cartilage directly and stimulates an inflam-
matory reaction in joint tissues at an early stage, afterGROSS OBSERVATIONS
Appearances of the knee joints were observed and body
weight changes were measured. They were classified into
swelling, reddening, and warmth, and each item was sub-
classified as mild, moderate, and severe on the basis of
severity. Severity of the lameness was also observed and
classified into three degrees.
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imental OA is a useful animal model, since the cartilage
degeneration is similar to the corresponding lesion in
human OA. Furthermore, using collagenase at a dose
lower than that of papain within a short period can con-
veniently induce the degeneration. In collagenase-injected
group, the swelling, reddening, and warmth of knee joints
were the most severe at 1 week after intraarticular injection
of collagenase, after which they gradually lessened. Fur-
thermore, they were not significantly different among the
collagenase-injected groups, but the number of lame rab-
bits in the SKI 306X-treated group was less than that of
the control group. The body weight decreased during the
first week after injection and then gradually increased
in collagenase-injected rabbits, and did not decrease in
saline-injected group.Histological examinations
Results of the histopathological evaluation are summa-
rized in Table II. Cartilages of the dorsal section of femoral
condyle and tibial plateau were examined by light
microscopy. In the saline-injected group, rabbits revealed
no significant histological changes in the articular cartilages
and synovial tissues (data not shown), whereas all other
treated groups developed different degrees of OA-like
degenerative changes in the articular cartilages, including
loss of the superficial layer, erosion, fibrillation, fissure,
disorganization of chondrocytes, and cluster formation.
Loss of superficial layer and erosion of cartilage were
significantly reduced in the SKI 306X-treated group [Fig.
1(c)] compared to those of the control and diclofenac-
treated groups [Fig. 1(a),(b)], respectively. The loss of PG,
determined through the safranin-O staining method, wasalso significantly reduced in the SKI 306X-treated group
compared to the control and diclofenac-treated groups in
accordance with the results of histopathologic examination
[Fig. 3(a)–(d)].
In synovial tissues, hyperplasia and hypertrophy of syno-
vial lining cells, infiltration of inflammatory cells, prolifer-
ation of granulation tissue, and vascularization were noted
in the control group [Fig. 2(a)]. The degree of synovial
changes was similar to that of the collagenase-treated
group in the diclofenac-treated group but showed signifi-
cant alleviation of lesions in the SKI 306X-treated group
compared to the control and diclofenac-treated groups [Fig.
2(b),(c), Table II). Global lesion score of the articular
cartilage and synovial tissue was significantly lower than
those of the control group and diclofenac-treated groups
(Table I). However, no significant difference in the global
lesion scores was observed between the control group and
diclofenac-treated groups, an indication that diclofenac did
not exert any significant protective effects. Other parenchy-
mal organs taken from the treated groups did not reveal
any remarkable histopathological change. As revealed
above, SKI 306X significantly inhibited the progression
of collagenase-induced OA-like changes without any
observable side effects.Table II
Histological evaluation scores of articular cartilage and synovial tissue of rabbits injected with collagenase
intraarticularly
0.5% CMC
(N=5)
Diclofenac
(N=5)
SKI 306X
(N=5)
Tibia condyle
Loss of superficial layer 3.0±0.7 3.2±0.8 1.8±0.4*
Erosion of cartilage 3.2±0.8 3.0±0.7 1.8±0.4*
Fibrillation and /or fissures 3.0±1.0 2.8±0.8 2.0±0.0
Disorganization of chondrocytes 2.6±0.9 2.4±0.5 1.8±0.4
Loss of chondrocyte 3.2±0.8 2.6±0.5 2.0±1.0
Cluster formation 2.4±0.5 2.4±0.9 1.6±0.5
Sum of score 17.4±3.4 16.4±2.9 11.0±1.6*
Femour plateau
Loss of superficial layer 3.8±0.4 3.8±0.4 2.4±0.5*
Erosion of cartilage 3.8±0.4 3.8±0.4 2.4±0.5*
Fibrillation and /or fissures 3.6±0.5 3.8±0.4 2.8±0.8
Disorganization of chondrocytes 3.4±0.5 3.8±0.4 2.6±0.9
Loss of chondrocyte 3.4±0.5 3.6±0.5 2.0±1.0*
Cluster formation 3.6±0.5 3.4±0.5 2.2±0.8*
Sum of score 21.6±1.9 22.2±2.4 14.4±4.4*
Synovial tissue
Hyperplasia of synovial lining cell 3.0±0.6 2.8±0.6 2.2±0.4
Hypertrophy of synovial lining layer 3.1±0.7 2.6±0.8 2.3±0.8
Infiltration of inflammatory cells 3.0±0.4 2.3±0.6 2.0±0.7*
Proliferation of granulation tissue 3.0±0.6 2.2±0.4 1.9±0.8
Vascularization 2.7±0.8 2.0±0.4 1.5±0.7*
Sum of score 14.8±2.7 11.9±2.6 9.9±2.8*
Each data represents the mean±S.D. *P<0.05 compared to 0.5% CMC treatment group.Discussion
Apart from surgical measures, treatment of OA has
generally been aimed at alleviating major complaints, such
as pain, swelling, and muscle tightness, and thus resulting
in improved mobility1.
Millions of individuals with OA have experienced relief of
joint pain and improvement in mobility as a result of taking
an NSAID. Despite their efficacy and universal use in OA
Osteoarthritis and Cartilage, Vol. 10, No. 6 475Figs 1 and 2. Representative sections of articular cartilage from femoral condyle (left column) and synovial tissue (right column). (1A, 2A)
Collagenase-injected group, (1B, 2B) diclofenac treated group, (1C, 2C) SKI 306X treated group. The global lesion score of the articular
cartilage and synovial tissue was significantly lower in SKI-306X treated group than control groups, respectively (P<0.05). H&E. ×200.treatment, the role of NSAIDs in managing OA is contro-
versial due to the negative effects of NSAIDs on cartilages
and the frequency and potential severity of side effects
(e.g., gastropathy, renal insufficiency, and neurologic com-plication)6. Recently, the discovery of two COX-2 isoforms
has provided fresh impetus for the use of NSAIDs in the
management of OA agents and development of selective
COX-2 inhibitors. The net effects of COX-2 up-regulation
476 J.-H. Choi et al.: Effects of SKI 306Xand prostaglandin overproduction on cartilage homeostasis
are not clear because prostaglandins have multiple direct
and indirect (anabolic and catabolic) effects on chondro-
cytes, which influence cartilage homeostasis20. Although
selective COX-2 inhibitors may reduce gastro-intestinal
troubles, whether these drugs exhibit useful effects on the
metabolism of cartilage and bone in OA joints has yet to be
determined. For several decades, intraarticular injection of
antiinflammatory steroids has been used to relieve the
symptoms of OA and to restore articular functions21. How-
ever, many physicians are reluctant to use steroid injec-
tions due to the potential deleterious side effects on
cartilage and bones, and the general recommendation is
that the same joint should not be injected more than two or
three times a year1. Therefore, needs are growing for the
development of agents that are capable of ameliorating the
symptoms of OA by modifying the underlying pathological
condition with limited side effects.
Oriental medicinal herbs, which have been widely used
for the treatment of various inflammatory diseases such as
lymphadenitis and arthritis in traditional Chinese medicine,
were selected and screened for their antiinflammatory,
analgesic, antiarthritic, and blood microcirculation-
enhancing activities and the inhibition of cartilage degen-eration enzyme activities. For such purposes, SKI 306X,
a new herbal extract, was prepared from a combination
of Clematis mandshurica, Trichosanthes kirilowii, and
Prunella vulgaris11–12. Clinical study on patients with OA
revealed that SKI 306X not only had a good analgesic
efficacy and safety profile, but also showed functional
improvements on the limitation of flexion, time taken to go
up and down a standard flight of stairs, duration of morning
stiffness, and softening of the affected knee joint13. Park et
al. reported that SKI 306X has superoxide anion dismu-
tation effect and its components herbs have hyaluronidase
inhibition effects11. Because it is well known that reactive
oxygen radicals (ROS) and hyaluronidase are implicated
cartilage degradation, we thought that SKI 306X might
have favorable chondroprotective effects. In vivo studies
using experimental models have shown that not all NSAIDs
affect OA cartilage lesions the same way. In spontaneous
murine OA model using C57BL/6 mice, diclofenac reduced
the incidence and severity of OA lesions, whereas sodium
salicylate and other NASAIDs increased the incidence and
severity22.
In this study, the effects of SKI 306X and its herbal
components on cartilage degradation were compared
with some representative OA drugs, such as diclofenacFig. 3. Representative Safranin-O-stained articular cartilages from femoral condyles. (3A) Normal articular cartilage, (3B) collagenase-
injected group, (3C) diclofenac treated group, (3D) SKI 306X treated group. The loss of safranin-O staining in the radial zone was
significantly reduced in SKI 306X treated group compared to collagenase-injected group. Safranin O staining. ×200.
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